Back to top

Subcutaneous Tislelizumab Trial Completion Signals Next Steps for BeOne Medicines and BeiGene

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines’ partner BeiGene has completed a Phase 1 study titled “...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)